Literature DB >> 33846629

Genetic in vivo engineering of human T lymphocytes in mouse models.

Tatjana Weidner1, Shiwani Agarwal1, Séverine Perian2, Floriane Fusil2, Gundula Braun1, Jessica Hartmann3, Els Verhoeyen4,5, Christian J Buchholz6,7.   

Abstract

Receptor targeting of vector particles is a key technology to enable cell type-specific in vivo gene delivery. For example, T cells in humanized mouse models can be modified by lentiviral vectors (LVs) targeted to human T-cell markers to enable them to express chimeric antigen receptors (CARs). Here, we provide detailed protocols for the generation of CD4- and CD8-targeted LVs (which takes ~9 d in total). We also describe how to humanize immunodeficient mice with hematopoietic stem cells (which takes 12-16 weeks) and precondition (over 5 d) and administer the vector stocks. Conversion of the targeted cell type is monitored by PCR and flow cytometry of blood samples. A few weeks after administration, ~10% of the targeted T-cell subtype can be expected to have converted to CAR T cells. By closely following the protocol, sufficient vector stock for the genetic manipulation of 10-15 humanized mice is obtained. We also discuss how the protocol can be easily adapted to use LVs targeted to other types of receptors and/or for delivery of other genes of interest.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33846629     DOI: 10.1038/s41596-021-00510-8

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  56 in total

1.  Electroporation enables plasmid vaccines to elicit CD8+ T cell responses in the absence of CD4+ T cells.

Authors:  Kelley Dayball; James Millar; Mark Miller; Yong Hong Wan; Jonathan Bramson
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

Review 2.  Paths to stemness: building the ultimate antitumour T cell.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

3.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Authors:  Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

Review 4.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

5.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

Review 6.  Gene therapy returns to centre stage.

Authors:  Luigi Naldini
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 7.  Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.

Authors:  Annika M Frank; Christian J Buchholz
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-17       Impact factor: 6.698

8.  Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing.

Authors:  Constanze Radek; Ornellie Bernadin; Katharina Drechsel; Nicole Cordes; Rita Pfeifer; Pia Sträßer; Mirella Mormin; Alejandra Gutierrez-Guerrero; François-Loïc Cosset; Andrew D Kaiser; Thomas Schaser; Anne Galy; Els Verhoeyen; Ian C D Johnston
Journal:  Hum Gene Ther       Date:  2019-12-03       Impact factor: 5.695

9.  In vivo generated human CAR T cells eradicate tumor cells.

Authors:  Shiwani Agarwal; Tatjana Weidner; Frederic B Thalheimer; Christian J Buchholz
Journal:  Oncoimmunology       Date:  2019-10-10       Impact factor: 8.110

10.  Optimized DNA electroporation for primary human T cell engineering.

Authors:  Zhang Zhang; Shunfang Qiu; Xiaopeng Zhang; Wei Chen
Journal:  BMC Biotechnol       Date:  2018-01-30       Impact factor: 2.563

View more
  4 in total

1.  In vivo generation of CAR T cells in the presence of human myeloid cells.

Authors:  Naphang Ho; Shiwani Agarwal; Michela Milani; Alessio Cantore; Christian J Buchholz; Frederic B Thalheimer
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-09       Impact factor: 5.849

Review 2.  Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies.

Authors:  Adrien Krug; Adriana Martinez-Turtos; Els Verhoeyen
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

3.  Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies.

Authors:  Audrey Page; Emilie Laurent; Didier Nègre; Caroline Costa; Véronique Pierre; Thierry Defrance; François-Loïc Cosset; Floriane Fusil
Journal:  Cancer Immunol Immunother       Date:  2021-11-08       Impact factor: 6.630

4.  Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics.

Authors:  Filippos T Charitidis; Elham Adabi; Frederic B Thalheimer; Colin Clarke; Christian J Buchholz
Journal:  Mol Ther Methods Clin Dev       Date:  2021-10-05       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.